The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
The Pivotal Role of NF-kB in the Pathogenesis and Therapeutics of Alzheimer’s Disease
Open accessAbstract
Alzheimer’s Disease (AD) is the most common neurodegenerative disease worldwide, with a high prevalence that is expected to double every 20 years. Besides the formation of Aβ plaques and neurofibrillary tangles, neuroinflammation is one the major phenotypes that worsens AD progression. Indeed, the nuclear factor-κB (NF-κB) is a well-established inflammatory transcription factor that fuels neurodegeneration. Thus, in this review, we provide an overview of the NF-κB role in the pathogenesis of AD, including its interaction with various molecular factors in AD mice models, neurons, and glial cells. Some of these cell types and molecules include reactive microglia and astrocytes, β-secretase, APOE, glutamate, miRNA, and tau protein, among others. Due to the multifactorial nature of AD development and the failure of many drugs designed to dampen AD progression, the pursuit of novel targets for AD therapeutics, including the NF-κB signaling pathway, is rising. Herein, we provide a synopsis of the drug development landscape for AD treatment, offering the perspective that NF-κB inhibitors may generate widespread interest in AD research in the future. Ultimately, the additional investigation of compounds and small molecules that target NF-κB signaling and the complete understanding of NF-κB mechanistic activation in different cell types will broaden and provide more therapeutic options for AD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Hydrogen peroxide mediates amyloid β protein toxicity
Behl, C. (1994) · Cell · doi:10.1016/0092-8674(94)90131-7 · Cited by 2,074
Neuroinflammation in Alzheimer's disease: current evidence and future directions
Calsolaro, V., & Edison, P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.010 · Cited by 1,726
Mattson, M., Cheng, B., Davis, D., Bryant, K., Lieberburg, I., & Rydel, R. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-02-00376.1992 · Cited by 1,627
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425 · cited 2×
“Particularly, APOEε4 was discovered to inhibit Aβ clearance from the brain interstitial fluid through various mechanisms [23].”
BackgroundThe Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease
Spires-Jones, T. L., & Hyman, B. T. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.004 · Cited by 1,201
Non-canonical NF-κB signaling pathway
Sun, S.-C. (2011) · Cell Research · doi:10.1038/cr.2010.177 · Cited by 1,197
ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050
Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease
Hock, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Müller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00294-0 · Cited by 777
SIRT1 Protects against Microglia-dependent Amyloid-β Toxicity through Inhibiting NF-κB Signaling
Chen, J., Zhou, Y., Mueller-Steiner, S., Chen, L.-F., Kwon, H., Yi, S., Mucke, L., & Gan, L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509329200 · Cited by 740
Current and future treatments for Alzheimer's disease
Yiannopoulou, K. G., & Papageorgiou, S. G. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612461679 · Cited by 677 · cited 2×
“This is perhaps unsurprising, given that acetylcholine and NMDAR play a vital role in cognitive function and excitotoxicity, respectively [36].”
BackgroundA phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
for the SCarlet RoAD Investigators, Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0318-y · Cited by 567
The Alzheimer's disease Beta-secretase enzyme, BACE1
Cole, S. L., & Vassar, R. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-22 · Cited by 550
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
Mechanisms of Aβ Clearance and Degradation by Glial Cells
Ries, M., & Sastre, M. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00160 · Cited by 527
Bcl10 activates the NF-κB pathway through ubiquitination of NEMO
Zhou, H., Wertz, I., O'Rourke, K., Ultsch, M., Seshagiri, S., Eby, M., Xiao, W., & Dixit, V. M. (2004) · Nature · doi:10.1038/nature02273 · Cited by 527
González-Reyes, R. E., Nava-Mesa, M. O., Vargas-Sánchez, K., Ariza-Salamanca, D., & Mora-Muñoz, L. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00427 · Cited by 527
Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer’s disease
Kaur, D., Sharma, V., & Deshmukh, R. (2019) · Inflammopharmacology · doi:10.1007/s10787-019-00580-x · Cited by 484
Mitochondria-targeted antioxidants protect against amyloid-β toxicity in Alzheimer's disease neurons
Manczak, M., Mao, P., Calkins, M. J., Cornea, A., Reddy, A. P., Murphy, M. P., Szeto, H. H., Park, B., & Reddy, P. H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100564 · Cited by 469
Chen, C.-H., Zhou, W., Liu, S., Deng, Y., Cai, F., Tone, M., Tone, Y., Tong, Y., & Song, W. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000149 · Cited by 433
Yan, S. D., Yan, S. F., Chen, X., Fu, J., Chen, M., Kuppusamy, P., Smith, M. A., Perry, G., Godman, G. C., Nawroth, P., et al. (1995) · Nature Medicine · doi:10.1038/nm0795-693 · Cited by 406
A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo
Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M. B., Gich, I., Agulló, J. M., Pérez, M., Avila, J., Guardia-Laguarta, C., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.025 · Cited by 368
Zhan, X., Stamova, B., & Sharp, F. R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00042 · Cited by 351
Microglial NF-κB drives tau spreading and toxicity in a mouse model of tauopathy
Wang, C., Fan, L., Khawaja, R. R., Liu, B., Zhan, L., Kodama, L., Chin, M., Li, Y., Le, D., Zhou, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29552-6 · Cited by 333
Bacteroides fragilis Lipopolysaccharide and Inflammatory Signaling in Alzheimer’s Disease
Lukiw, W. J. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01544 · Cited by 288
Advances in developing novel therapeutic strategies for Alzheimer’s disease
Cao, J., Hou, J., Ping, J., & Cai, D. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0299-8 · Cited by 285
Regulation of NF-κB by NSD1/FBXL11-dependent reversible lysine methylation of p65
Lu, T., Jackson, M. W., Wang, B., Yang, M., Chance, M. R., Miyagi, M., Gudkov, A. V., & Stark, G. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912493107 · Cited by 280
Self-citationBACE1 inhibitors: Current status and future directions in treating Alzheimer's disease
Moussa‐Pacha, N. M., Abdin, S. M., Omar, H. A., Alniss, H., & Al‐Tel, T. H. (2020) · Medicinal Research Reviews · doi:10.1002/med.21622 · Cited by 274
Harkany, T., Ábrahám, I., Timmerman, W., Laskay, G., Tóth, B., Sasvári, M., Kónya, C., Sebens, J. B., Korf, J., Nyakas, C., et al. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00164.x · Cited by 273
Thawkar, B. S., & Kaur, G. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.11.010 · Cited by 249
Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial
Butchart, J., Brook, L., Hopkins, V., Teeling, J., Püntener, U., Culliford, D., Sharples, R., Sharif, S., McFarlane, B., Raybould, R., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001617 · Cited by 248
Rivastigmine for Alzheimer's disease
Birks, J. S., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub3 · Cited by 247
PRMT5 dimethylates R30 of the p65 subunit to activate NF-κB
Wei, H., Wang, B., Miyagi, M., She, Y., Gopalan, B., Huang, D.-B., Ghosh, G., Stark, G. R., & Lu, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311784110 · Cited by 237
Self-citationCalcium signaling in Alzheimer's disease & therapies
Tong, B. C.-K., Wu, A. J., Li, M., & Cheung, K.-H. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.07.018 · Cited by 231
Alzheimer disease and aducanumab: adjusting our approach
Selkoe, D. J. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0205-1 · Cited by 208
Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline
Ryan, J., Storey, E., Murray, A. M., Woods, R. L., Wolfe, R., Reid, C. M., Nelson, M. R., Chong, T. T. J., Williamson, J. D., Ward, S. A., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009277 · Cited by 182
Neuronal Gene Targets of NF-κB and Their Dysregulation in Alzheimer's Disease
Snow, W. M., & Albensi, B. C. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00118 · Cited by 180
Nuclear factor‐kappa β as a therapeutic target for Alzheimer's disease
Jha, N. K., Jha, S. K., Kar, R., Nand, P., Swati, K., & Goswami, V. K. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14687 · Cited by 178
Amyloid beta deregulates astroglial mGluR5‐mediated calcium signaling via calcineurin and Nf‐kB
Lim, D., Iyer, A., Ronco, V., Grolla, A. A., Canonico, P. L., Aronica, E., & Genazzani, A. A. (2013) · Glia · doi:10.1002/glia.22502 · Cited by 169
Apolipoprotein E4 enhances brain inflammation by modulation of the NF-κB signaling cascade
Ophir, G., Amariglio, N., Jacob-Hirsch, J., Elkon, R., Rechavi, G., & Michaelson, D. M. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.05.002 · Cited by 166
Srinivasan, M., & Lahiri, D. K. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.989834 · Cited by 164
Donepezil in Alzheimer’s disease: from conventional trials to pharmacogenetics
Cacabelos, R. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a908 · Cited by 164
Medeiros, R., Kitazawa, M., Passos, G. F., Baglietto-Vargas, D., Cheng, D., Cribbs, D. H., & LaFerla, F. M. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.01.051 · Cited by 163
NF‐κB pathway: a target for preventing β‐amyloid (Aβ)‐induced neuronal damage and Aβ42 production
Valerio, A., Boroni, F., Benarese, M., Sarnico, I., Ghisi, V., Bresciani, L. G., Ferrario, M., Borsani, G., Spano, P., & Pizzi, M. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04722.x · Cited by 154
Aducanumab Therapy to Treat Alzheimer’s Disease: A Narrative Review
Beshir, S. A., Aadithsoorya, A. M., Parveen, A., Goh, S. S. L., Hussain, N., & Menon, V. B. (2022) · International Journal of Alzheimer s Disease · doi:10.1155/2022/9343514 · Cited by 131
Regulation of Complement Factor H (CFH) by Multiple miRNAs in Alzheimer’s Disease (AD) Brain
Lukiw, W. J., & Alexandrov, P. N. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8234-4 · Cited by 130
Regulation of TREM2 expression by an NF-кB-sensitive miRNA-34a
Zhao, Y., Bhattacharjee, S., Jones, B. M., Dua, P., Alexandrov, P. N., Hill, J. M., & Lukiw, W. J. (2013) · Neuroreport · doi:10.1097/wnr.0b013e32835fb6b0 · Cited by 128
Update on the use of memantine in Alzheimer’s disease
van Marum, R. J. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s4048 · Cited by 127
Zhao, Y., Bhattacharjee, S., Jones, B. M., Hill, J. M., Dua, P., & Lukiw, W. J. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8595-3 · Cited by 119
Lopez Lopez, C., Tariot, P. N., Caputo, A., Langbaum, J. B., Liu, F., Riviere, M., Langlois, C., Rouzade‐Dominguez, M., Zalesak, M., Hendrix, S., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.02.005 · Cited by 116 · cited 1×
“CNP520 Inhibits BACE1 Unknown Phase 2/3 clinical trial [73] ClinicalTrials.”
BackgroundChapter 24 NF‐KappaB Dimers in the Regulation of Neuronal Survival
Sarnico, I., Lanzillotta, A., Benarese, M., Alghisi, M., Baiguera, C., Battistin, L., Spano, P., & Pizzi, M. (2009) · International review of neurobiology · doi:10.1016/s0074-7742(09)85024-1 · Cited by 105
Kong, F., Jiang, X., Wang, R., Zhai, S., Zhang, Y., & Wang, D. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01967-2 · Cited by 104
NF-κB: Regulation by Methylation
Lu, T., & Stark, G. R. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1022 · Cited by 101
Self-citationHe, W., Wang, C., Chen, Y., He, Y., & Cai, Z. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.06.006 · Cited by 96
Cirillo, C., Capoccia, E., Iuvone, T., Cuomo, R., Sarnelli, G., Steardo, L., & Esposito, G. (2015) · BioMed Research International · doi:10.1155/2015/508342 · Cited by 95
NF-κB-regulated, proinflammatory miRNAs in Alzheimer's disease
Lukiw, W. J. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt150 · Cited by 90
Lu, T., Jackson, M. W., Singhi, A. D., Kandel, E., Yang, M., Zhang, Y., Gudkov, A. V., & Stark, G. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908560106 · Cited by 84
Self-citationDanger-Sensing/Patten Recognition Receptors and Neuroinflammation in Alzheimer’s Disease
Chiarini, A., Armato, U., Hu, P., & Prà, I. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239036 · Cited by 81
Cai, Z., Zhao, Y., Yao, S., & Zhao, B. (2011) · Pharmacological Reports · doi:10.1016/s1734-1140(11)70504-7 · Cited by 65
Nimodipine in the Treatment of Probable Alzheimerʼs Disease
Morich, F., Bieber, F., Lewis, J. M., Kaiser, L., Cutler, N. R., Escobar, J. I., Willmer, J., Petersen, R. C., & Reisberg, . (1996) · Clinical Drug Investigation · doi:10.2165/00044011-199611040-00001 · Cited by 61
Liu, S., Breitbart, A., Sun, Y., Mehta, P. D., Boutajangout, A., Scholtzova, H., & Wisniewski, T. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12484 · Cited by 60
Quan, X., Yue, W., Luo, Y., Cao, J., Wang, H., Wang, Y., & Lu, Z. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13191 · Cited by 47
Prabhu, L., Han, W., Chen, L., Demir, Ö., Sandusky, G. E., Sun, E., Wang, J., Mo, J., Zeng, L., Fishel, M. L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18102 · Cited by 47
Self-citationRegulation of Human Brain Microvascular Endothelial Cell Adhesion and Barrier Functions by Memantine
Wang, F., Zou, Z., Gong, Y., Yuan, D., Chen, X., & Sun, T. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0917-x · Cited by 46
[O2–14–05]: PRECLINICAL CHARACTERIZATION OF AN ANTIBODY [LY3303560] TARGETING AGGREGATED TAU
Alam, R., Driver, D. A., Wu, S., Lozano, E., Key, S., Hole, J. T., Hayashi, M. L., & Lu, J. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.07.227 · Cited by 45
Du, Y., Chen, X., Wei, X., Bales, K. R., Berg, D. T., Paul, S. M., Farlow, M. R., Maloney, B., Ge, Y., & Lahiri, D. K. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2005.02.001 · Cited by 38
Verapamil and Alzheimer’s Disease: Past, Present, and Future
Popović, N., Morales-Delgado, N., Mena, D. V., Alonso, A., Martínez, M. P., Bleda, M. C., & Popović, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00562 · Cited by 36
Lynch, S. Y., Kaplow, J. M., Zhao, J., Dhadda, S., Luthman, J., & Albala, B. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.07.213 · Cited by 35
ST101 induces a novel 17kDa APP cleavage that precludes Aβ generation in vivo
Green, K. N., Khashwji, H., Estrada, T., & LaFerla, F. M. (2011) · Annals of Neurology · doi:10.1002/ana.22325 · Cited by 34
Regulation of SET Gene Expression by NFkB
Feng, Y., Li, X., Zhou, W., Lou, D., Huang, D., Li, Y., Kang, Y., Xiang, Y., Li, T., Zhou, W., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9967-2 · Cited by 33
Mitochondria-Targeted Molecules as Potential Drugs to Treat Patients With Alzheimer's Disease
Reddy, A. P., & Reddy, P. H. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.12.010 · Cited by 31
Curcumin and Novel Synthetic Analogs in Cell-Based Studies of Alzheimer’s Disease
Gagliardi, S., Franco, V., Sorrentino, S., Zucca, S., Pandini, C., Rota, P., Bernuzzi, S., Costa, A. C., Sinforiani, E., Pansarasa, O., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01404 · Cited by 30
Liang, Z., Wang, X., Li, L., Wang, Y., Chen, R., Chuang, D., Chase, T. N., & Qin, Z. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21248 · Cited by 27
Recent Tau-Targeted Clinical Strategies for the Treatment of Alzheimer's Disease
Lee, H. E., Lim, D., Lee, J. Y., Lim, S. M., & Pae, A. N. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0151 · Cited by 27
Lindsay, A. K., Hickman, D., & Srinivasan, M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111405 · Cited by 26
Galantamine Demonstrates Efficacy and Safety in Elderly Patients With Alzheimer Disease
Marcusson, J. O., Bullock, R. A., Gauthier, S. G., Kurz, A., & Schwalen, S. (2003) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200307003-00005 · Cited by 21
A small-molecule DS44170716 inhibits Ca2+-induced mitochondrial permeability transition
Kon, N., Satoh, A., & Miyoshi, N. (2017) · Scientific Reports · doi:10.1038/s41598-017-03651-7 · Cited by 17
Hints of a Therapeutic Vaccine for Alzheimer's?
Winblad, B. G., & Blum, K. I. (2003) · Neuron · doi:10.1016/s0896-6273(03)00297-6 · Cited by 14
Sarnico, I., Boroni, F., Benarese, M., Alghisi, M., Valerio, A., Battistin, L., Spano, P., & Pizzi, M. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-007-0016-1 · Cited by 12
NF-κB and Cancer Therapy Drugs
Motolani, A., Martin, M., Sun, M., & Lu, T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00064-5 · Cited by 8
Self-citationO’Gorman, C., Jones, A., & Tabuteau, H. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.06.717 · Cited by 1
Cited by
NF-κB in inflammation and cancer
Mao, H., Zhao, X., & Sun, S.-C. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01310-w · Cited by 489
Microglia and Astrocytes in Alzheimer’s Disease: Significance and Summary of Recent Advances
Deng, Q., Wu, C., Parker, E., Liu, T. C.-Y., Duan, R., & Yang, L. (2023) · Aging and disease · doi:10.14336/ad.2023.0907 · Cited by 102
“In addition, astroglia NF-κB activation contributes to maintaining brain homeostasis, which is also pivotal to neurodegeneration, causing pro-inflammatory cytokine formation and increasing excitotoxicity in AD [203].”
BackgroundAmeliMojarad, M., & AmeliMojarad, M. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14856 · Cited by 73
Oxidative Stress in Alzheimer’s Disease: The Shortcomings of Antioxidant Therapies
Pappolla, M. A., Martins, R. N., Poeggeler, B., Omar, R. A., & Perry, G. (2024) · Journal of Alzheimer's Disease · doi:10.3233/jad-240659 · Cited by 29
AdipoRon’s Impact on Alzheimer’s Disease—A Systematic Review and Meta-Analysis
Barbalho, S. M., Laurindo, L. F., de Oliveira Zanuso, B., da Silva, R. M. S., Gallerani Caglioni, L., Nunes Junqueira de Moraes, V. B. F., Fornari Laurindo, L., Dogani Rodrigues, V., da Silva Camarinha Oliveira, J., Beluce, M. E., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020484 · Cited by 18
Metadata
- Authors
- Sun, E., Motolani, A., Campos, L., & Lu, T.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-08-11
- Volume
- 23
- Issue
- 16
- Pages
- 8972
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4291000683
- Cited by
- 361
- References
- 82
- FWCI
- 38.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.